Table I.
Frequency of CTCs and their subtypes in patients with breast cancera.
| Aneuploid CTCs, n (%) | Diploid CTCs, n (%) | Triploid CTCs, n (%) | Tetraploid CTCs, n (%) | Multipoid (≥5) CTCs, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | Total | Total | CK+ | Total | CK+ | Total | CK+ | Total | CK+ | Total | CK+ |
| Sample type | |||||||||||
| Health donors | 10 | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Benign tumors | 26 | 8 (30.77) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 8 (30.77) | 0 (0.00) | 2 (7.69) | 0 (0.00) | 2 (7.69) | 0 (0.00) |
| Breast cancers | 184 | 167 (90.76) | 33 (4.88) | 5 (2.72) | 5 (2.72) | 147 (79.89) | 6 (3.26) | 68 (36.96) | 4 (2.17) | 76 (41.30) | 8 (4.35) |
| Tumor size | |||||||||||
| T1 | 80 | 73 (91.25) | 8 (10.00) | 3 (3.75) | 3 (3.75) | 66 (82.50) | 2 (2.50) | 34 (42.5) | 1 (1.25) | 33 (41.25) | 3 (3.75) |
| T2 | 68 | 63 (92.65) | 5 (7.35) | 1 (1.47) | 1 (1.47) | 52 (76.47) | 2 (2.94) | 23 (33.82) | 1 (1.47) | 24 (35.29) | 3 (4.41) |
| T3 | 10 | 9 (90.00) | 1 (10.00) | 0 (0.00) | 0 (0.00) | 9 (90.00) | 0 (0.00) | 4 (40.00) | 1 (10.00) | 8 (80.00) | 1 (10.00) |
| Molecular typing | |||||||||||
| Luminal A | 30 | 24 (80.00) | 5 (16.67) | 1 (3.33) | 1 (3.33) | 20 (66.67) | 2 (6.67) | 14 (46.67) | 2 (6.67) | 8 (26.67) | 2 (6.67) |
| Luminal B | 89 | 80 (89.89) | 11 (12.36) | 4 (4.49) | 4 (4.49) | 70 (78.65) | 3 (3.37) | 28 (31.46) | 2 (2.25) | 36 (40.45) | 5 (5.62) |
| Her2-positive | 35 | 34 (97.14) | 1 (2.86) | 0 (0.00) | 0 (0.00) | 30 (85.71) | 1 (2.86) | 16 (45.71) | 0 (0.00) | 20 (57.14) | 0 (0.00) |
| Triple-negative | 12 | 12 (100.00) | 1 (8.33) | 0 (0.00) | 0 (0.00) | 11 (91.67) | 0 (0.00) | 4 (33.33) | 0 (0.00) | 4 (33.33) | 1 (8.33) |
| Clinical stage | |||||||||||
| I | 52 | 48 (92.31) | 6 (11.54) | 2 (3.85) | 2 (3.85) | 42 (80.77) | 1 (1.92) | 22 (42.31) | 1 (1.92) | 20 (38.46) | 3 (5.77) |
| II | 61 | 59 (96.72) | 4 (6.56) | 2 (3.28) | 2 (3.28) | 53 (86.89) | 1 (1.64) | 25 (40.98) | 1 (1.64) | 28 (45.90) | 2 (3.28) |
| III | 39 | 34 (87.18) | 4 (10.26) | 0 (0.00) | 0 (0.00) | 28 (71.79) | 2 (5.13) | 12 (30.77) | 1 (2.56) | 16 (41.03) | 2 (5.13) |
| IV | 6 | 5 (83.33) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (50.00) | 0 (0.00) | 2 (33.33) | 0 (0.00) | 3 (50.00) | 0 (0.00) |
| Lymph node status | |||||||||||
| Metastasis | 80 | 73 (91.25) | 7 (8.75) | 2 (2.50) | 2 (2.50) | 64 (80.00) | 3 (3.75) | 27 (33.75) | 1 (1.25) | 36 (45.00) | 3 (3.75) |
| Non-metastasis | 85 | 79 (92.94) | 8 (9.41) | 3 (3.53) | 3 (3.53) | 69 (81.18) | 2 (2.35) | 36 (42.35) | 2 (2.35) | 35 (41.18) | 4 (4.71) |
a
Number of individuals with CTC positive and detection rate in patients with different disease, tumor size and molecular typing. The numbers in parentheses indicate the frequency of CK-positive CTCs. CTC, circulating tumor cell; CK, cytokeratin; Her2, herceptin 2.